01105nas a2200421   4500000000100000000000100001008004100002653001500043653002600058653001500084653007600099653001500175653001600190653001100206653001500217653001400232653004900246653004800295653001500343653002000358653001300378653001300391653001000404653000700414100001100421700001600432700001800448700001600466700001700482700001100499700001500510700001400525245009500539250001500634300001200649490000800661020001400669       2022                            d10aAdolescent10a*Antipsychotic Agents10aCitalopram10a*Diabetes Mellitus, Type 2/chemically induced/drug therapy/epidemiology10aFluoxetine10aFluvoxamine10aHumans10aParoxetine10aSerotonin10aSerotonin Plasma Membrane Transport Proteins10aSerotonin Uptake Inhibitors/adverse effects10aSertraline10aAntidepressants10aChildren10adiabetes10aSSRIs10aUk1 aT. Cao1 aC. Filliter1 aF. Montastruc1 aO. H. Y. Yu1 aE. Fergusson1 aS. Rej1 aL. Azoulay1 aC. Renoux00aSelective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths  a2022/09/10  a231-2370 v318  a0165-0327